Valuation
- Market cap
- 7,253,527,000
- Revenue TTM
- $0
- Net income TTM
- $-505,610,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 864,800
- Avg volume
- 1,509,508
- Day's range
- $33.87 – $34.84
- Shares out
- 206,948,000
- Stochastic %K
- 64%
- Beta
- 0.95
- Analysts
- Moderate Buy
- Price target
- $46.72
Company profile
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. T...
Show more
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 917 410 3120
- Website
- https://immunovant.com
- Address
- 1000 Park Forty Plaza, Suite 210, Durham, United States
Latest news
No headlines yet.
Stocktwits
Merlintrader
Nov 10, 9:52 PM
$IMVT Immunovant (IMVT): cash
$722.3M; 600 mg IMVT-1402 met RA endpoint
Free weekly catalyst newsletter:
https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13
Not investment advice.
0 replies
shoc24
Nov 10, 6:07 AM
$IMVT reported earnings before the open today. GAAP EPS beat estimates: -
$0.47 vs. -
$0.74 expected, according to Stock Meadow.
0 replies
Merlintrader
Nov 9, 4:28 PM
$IMVT Immunovant Provides Corporate Updates and Reports Results for Quarter Ended September 30, 2026 (Nov 9)
• IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 of the potentially registrational D2T RA trial.
• FDA discussions are planned for later this year on the path forward for the D2T RA registrational program.
Full hub (catalysts, filings & latest news):
https://www.merlintrader.com/immunovant-stock-hub?utm_source=stocktwits&utm_medium=social&utm_campaign=st-hub-giro&utm_content=imvt
Free weekly catalyst newsletter — no free trials, no logins, FREE is FREE:
https://merlintrader.beehiiv.com/subscribe?utm_source=stocktwits&utm_medium=social&utm_campaign=st-hub-giro&utm_content=imvt
Not investment advice.
0 replies
EarningsInsider
Nov 9, 2:01 PM
https://www.marketbeat.com/earnings/reports/2026-11-9-immunovant-inc-stock/
$IMVT Immunovant Earnings Transcript
OpenOutcrier
Nov 9, 1:51 PM
$IMVT (+10.5% pre) Immunovant, Inc. (IMVT) Tops Q2 EPS by 27c
https://ooc.bz/l/120498
0 replies
StocktwitsEarnings
Nov 9, 1:49 PM
$IMVT Q2 '27 Earnings Results & Recap
• Reported GAAP EPS of -
$0.41 up 36.92% YoY
• Immunovant expects
$722.3M of cash and cash equivalents as of September 30, 2026 to fund operating expenses and capital expenditure requirements through potential IMVT-1402 commercial launch in GD under its current operating plan.
0 replies
GTA_Terminal
Nov 9, 1:35 PM
Unusual options activity in
$IMVT. Money on both sides, which usually means traders expect a move but don't agree on the direction.
Read the full article for the full details:
https://globaltradersacademy.com/articles/immunovant-imvt-technical-levels-options-flow-mixed-between-28-70-and-30-61?utm_source=stocktwits&utm_medium=social
